ArticleCureus2025
Post-Shingrix Vaccination Guillain-Barré Syndrome Presentation in the Emergency Department: A Case Report and Literature Review.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Guillain-Barré syndrome (GBS) is a rare neurological disorder of the peripheral nervous system. We present a case of 65-year-old female patient who developed GBS post-Shingrix inoculation. The patient, with no recognised GBS risk factors, presented with acute bilateral ascending lower limb peripheral nerve pathology eight days post-Shingrix vaccination. Other than abnormal lower limb neurological findings, her examination and biochemical results were normal. Imaging indicated possible inflammation in bilateral lumbosacral plexus. Treatment with IVIG achieved some symptom improvement, but she did not return to her baseline. Functionally, she was able to stand and mobilise 50 metres with a four-wheeled walker. Our case report highlights the importance of considering this syndrome as a differential in patients with no common GBS risk factors post-Shingrix vaccination, despite the large gap in the literature. Further studies into vaccine components as autoimmune triggers are necessary to minimise risk of GBS in the post-vaccination period.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.